

Cancer research publications by Sheba scientists

2006

- 1) Akagi T, Yin D, Kawamata N, Bartram CR, Hofmann WK, Wolf I, Miller CW, Koeffler P. Methylation analysis of asparagines synthetase gene in acute lymphoblastic leukemia cells. *Leukemia*. 2006 Jul;20(7):1303-6. (IF 6.612)
- 4) 2) Akavia UD, Shur I, Rechavi G, Benayahu D. Transcriptional profiling of mesenchymal stromal cells from young and old rats in response to Dexamethasone. *BMC Genomics*. 2006 Apr 27; 7:95. (IF 4.092)
- 2) 3) Amariglio N, Jacob-Hirsch J, Shimoni A, Leiba M, Rechavi G, Nagler A. Changes in Gene Expression Pattern following Granulocyte Colony-Stimulating Factor Administration to Normal Stem Cell Sibling Donors. *Acta Haematol*. 2006 Nov 9;117(2):68-73. (IF 1.229)
- 3) 4) Apter S, Shemesh J, Raanani P, Portnoy O, Thaler M, Zissin R, Ezra D, Rozenman J, Pfeffer R, Hertz M. Cardiovascular calcifications after radiation therapy for Hodgkin lymphoma: computed tomography detection and clinical correlation. *Coron Artery Dis*. 2006 Mar;17(2):145-51. (IF 1.529)
- 4) 5) Avivi A, Ashur-Fabian O, Joel A, Trakhtenbrot L, Adamsky K, Goldstein I, Amariglio N, Rechavi G, Nevo E. P53 in blind subterranean mole rats - loss-of-function versus gain-of-function activities on newly cloned Spalax target genes. *Oncogene*. 2006 Oct 16; [Epub ahead of print]. (IF 6.872)
- 5) 6) Bakhanashvili M, Rahav G. The incorporation of nucleoside analogs by human immunodeficiency virus type 1 reverse transcriptase decreases in the presence of polyamines. *FEBS Letters* 2006 580: 5363-5370. (IF 3.415)
- 6) 7) Bar-Natan M, Nagler A. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder. *IMAJ*. 2006 Mar;8(3):205-7. (IF 0.547) No abstract available
- 7) 8) Basel-Vanagaite L, Attia R, Yahav M, Ferland RJ, Anteki L, Walsh CA, Olender T, Straussberg R, Magal N, Taub E, Drasinover V, Alkelai A, Bercovich D, Rechavi G, Simon AJ, Shohat M. The CC2D1A, a member of a new gene family with C2 domains, is involved in autosomal recessive non-syndromic mental retardation. *J Med Genet*. 2006 Mar; 43(3):203-10. (IF 4.330)

- 8)9) Basel-Vanagaite L, Muncher L, Straussberg R, Pasmanik-Chor M, Yahav M, Rainshtein L, Walsh CA, Magal N, Taub E, Drasinover V, Shalev H, Attia R, Rechavi G, Simon AJ, Shohat M. Mutated nup62 causes autosomal recessive infantile bilateral striatal necrosis. *Ann Neurol.* 2006 Aug;60(2):214-22 (IF 7.571)
- 9)10) Beiner ME, Niv H, Haklai R, Elad-Sfadia G, Kloog Y, Ben-Baruch G. Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells. *Int J Gynecol Cancer.* 2006 Jan-Feb;16 Suppl 1:200-6. (IF 1.427)
- 10)11) Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, Lynch HT, Friedman E, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. *Gynecol Oncol.* 2006 Sep 8; [Epub ahead of print] (IF 2.251)
- 11)12) Ben-Horin S, Green PH, Bank I, Chess L, Goldstein I. Characterizing the circulating, gliadin-specific CD4+ memory T cells in patients with celiac disease: linkage among memory function, gut homing, and Th1 polarization. *J Leukoc Biol.* 2006 Apr;79(4):676-85 (IF 4.627)
- 12)13) Berger R, Lin D.I., Waltregny D, Graner E, Garraway L.A, Signoretti S, Hahn W.C, Loda M. Androgen-dependent regulation of Her-2/neu In Prostate Cancer Cells. *Cancer Res.* 2006; 66(11) 5723-28 (IF 7.616)
- 13)14) Bercovitch M, Adunsky A. High Doses Controlled -Release Oxycodone in Hospice Care". *J Pain Palliat Care Pharmacother* 2006; 20 (4)
- 14)15) Besser MJ, Treves AJ, Itzhaki O, Hardan I, Nagler A, Papa MZ, Catane R, Winkler E, Salmon-Zifroni B, Schachter J. Adoptive Cell Therapy for Metastatic Melanoma Patients: Pre-clinical Development at the Sheba Medical Center; *IMAJ* 2006 Mar;8(3):164-8 (IF 0.547)
- 15)16) Blum R, Nakdimon I, Goldberg L, Elkorn R, Shamir R, Rechavi G, Kloog Y. E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to ras inhibition. *Int J Cancer.* 2006 Aug 1;119(3):527-38 (IF 4.700)
- 16)17) Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. *Mol Cancer Ther.* 2006 Sep; 5(9):2337-47. (IF 5.171)
- 17)18) Buhard O, Cattaneo F, Wong YF, Yim SF, Friedman E, Flejou JF, Duval A, Hamelin R. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to

determine the microsatellite instability status of human tumors. J Clin Oncol. 2006 Jan 10; 24(2):241-51 (IF 11.810)

18)19) Catane R, Beck A, Inbar Y, Rabin T, Shabshin N, Hengst S, Pfeffer RM, Hananel A, Dogadkin O, Liberman B, Kopelman D. MR-guided focused ultrasound surgery (MRgFUS) for the palliation of pain in patients with bone metastases--preliminary clinical experience. Ann Oncol. 2006 Oct 9; [Epub ahead of print] (IF 4.319)

19)20) Cherny NI, Catane R, Kosmidis PA. Problems of opioid availability and accessibility across Europe: ESMO tackles the regulatory causes of intolerable and needless suffering. Ann Oncol. 2006 Jun;17(6):885-7; (IF 4.319) No abstract available

20)21) Dagan E, Laitman Y, Levanon N, Feuer A, Sidi AA, Baniel J, Korach Y, Baruch GB, Friedman E, Gershoni-Baruch R. The 471delAAAG Mutation and C353T Polymorphism in the RNASEL Gene in Sporadic and Inherited Cancer in Israel. Fam Cancer. 2006;5(4):389-95

21)22) Dagan-Berger M, Feniger-Barish R, Avniel S, Wald H, Galun E, Grabovsky V, Alon R, Nagler A, Ben-Baruch A, Peled A. Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11. Blood. 2006 May 15;107(10):3821-31 (IF 10.131)

22)23) Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J, Maziarz R, Olavarria E, Verdonck L, Schaefer K, Boqui C, Faber E, Nagler A et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006 Apr; 91(4):452-9. (IF 4.575)

23)24) Dekel B, Zangi L, Shezen E, Reich-Zeliger S, Eventov-Friedman S, Katchman H, Jacob-Hirsch J, Amariglio N, Rechavi G, Margalit R, Reisner Y. Isolation and Characterization of Nontubular Sca-1+Lin- Multipotent Stem/Progenitor Cells from Adult Mouse Kidney. J Am Soc Nephrol. 2006 Dec;17(12):3300-14 (IF 7.240)

24)25) Dekel B, Metsuyanim S, Schmidt-Ott KM, Friedman E, Jacob-Hirsch J, Simon A, Pinthus J, Mor Y, Barasch J, Amariglio N, Reisner Y, Kaminski N, Rechavi G. Multiple Imprinted and Stemness Genes Provide a Link between Normal and Tumor Progenitor Cells of the Developing Human Kidney. Cancer Res. 2006 Jun 15;66(12):6040-9. (IF 7.616)

25)26) Dekel B, Shezen E, Even-Tov-Friedman S, Katchman H, Margalit R, Nagler A, Reisner Y. Transplantation of human hematopoietic stem cells into ischemic and growing kidneys suggests a role in vasculogenesis but not tubulogenesis. Stem Cells. 2006 May;24(5):1185-93 (IF 6.094)

- 26)27) Dror N, Alter-Koltunoff M, Azriel A, Amariglio N, Jacob-Hirsch J, Zeligson S, Morgenstern A, Tamura T, Hauser H, Rechavi G, Ozato K, Levi BZ. Identification of IRF-8 and IRF-1 target genes in activated macrophages. *Mol Immunol.* 2007 Jan;44(4):338-46; (IF 4.307)
- 27)28) Eliashar R, Ochana M, Maly B, Pines M, Sichel JY, Nagler A. Halofuginone prevents subglottic stenosis in a canine model. *Ann Otol Rhinol Laryngol.* 2006 May; 115(5):382-6.
- 28)29) Enk CD, Jacob-Hirsch J, Gal H, Verbovetski I, Amariglio N, Mevorach D, Ingber A, Givol D, Rechavi G, Hochberg M. The UVB-induced gene expression profile of human epidermis in vivo is different from that of cultured keratinocytes. *Oncogene.* 2006 Apr 27;25(18):2601-14; (IF 6.872)
- 29)30) Eventov-Friedman S, Tchorsh D, Katchman H, Shezen E, Aronovich A, Hecht G, Dekel B, Rechavi G, Blazar BR, Feine I, Tal O, Freud E, Reisner Y. Embryonic Pig Pancreatic Tissue Transplantation for the Treatment of Diabetes. *PLoS Med.* 2006 Jun 20;3(7):e215 (IF 8.389)
- 30)31) Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. *JAMA.* 2006 Jul 12;296(2):185-92. (IF 23.494)
- 31)32) Friedman E, Pinthus JH, Kopolovic J, Ramon J, Mor O, Mor Y. Expression of cyclooxygenase-2 in Wilms tumor: immunohistochemical study using tissue microarray methodology. *J Urol.* 2006 Oct; 176(4 Pt 2):1747-50. (IF 3.592)
- 32)33) Friedman E, et al. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. *Breast Cancer Res.* 2006 Mar 21;8(2):R15 (IF 4.026)
- 33)34) Gal I, Kimmel G, Gershoni-Baruch R, Papa MZ, Dagan E, Shamir R, Friedman E. A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women. *Eur J Cancer.* 2006 May;42(8):1129-34; (IF 3.706)
- 34)35) Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, Nagler A, Tavor S, Ein-Dor L, Lapidot T, Domany E, Rechavi G, Givol D. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. *Leukemia.* 2006 Dec;20(12):2147-54. (IF 6.612)

- 35)36) Galski H, Sivan H, Lazarovici P, Nagler A. In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies. Leuk Res. 2006 Sep;30(9):1151-8. (IF 2.372)
- 36)37) Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Grusfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43. (IF 44.016)
- 37)38) Gnainsky Y, Kushnirsky Z, Bilu G, Hagai Y, Genina O, Volpin H, Bruck R, Spira G, Nagler A, Kawada N, Yoshizato K, Reinhardt DP, Libermann TA, Pines M. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. Cell Tissue Res. 2006 Dec 19 (IF 2.383)
- 38)39) Gnainsky Y, Spira G, Paizi M, Bruck R, Nagler A, Genina O, Taub R, Halevy O, Pines M. Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone. Cell Tissue Res. 2006 Jun;324(3):385-94; (IF 2.383)
- 39)40) Goichberg P, Kalinkovich A, Borodovsky N, Tesio M, Petit I, Nagler A, Hardan I, Lapidot T. cAMP-induced PKCzeta activation increases functional CXCR4 expression on human CD34+ hematopoietic progenitors. Blood. 2006 Feb 1; 107(3):870-9. (IF 10.131)
- 40)41) Goldstein I, Ben-Horin S, Koltakov A, Chermoshnuk H, Polevoy V, Berkun Y, Amariglio N, Bank I. {alpha}1beta1 Integrin+ and Regulatory Foxp3+ T Cells Constitute Two Functionally Distinct Human CD4+ T Cell Subsets Oppositely Modulated by TNF{alpha} Blockade. J Immunol. 2007 Jan 1;178(1):201-10. (IF 6.387)
- 41)42) Goldstein G, Toren A, Nagler A. Human umbilical cord blood biology, transplantation and plasticity. Curr Med Chem. 2006; 13(11):1249-59. (IF 4.904)
- 42)43) Gorin NC, Labopin M, Boiron JM, Theorin N, Littlewood T, Slavin S, Greinix H, Cahn JY, Alessandrino EP, Rambaldi A, Nagler A, Polge E, Rocha V; Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. Results of genoindentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2006 Aug 20; 24(24):3959-66. (IF 11.810)

- 43)44) Gotlieb WH, Barchana M, Ben-Baruch G, Friedman E. Malignancies following bilateral salpingo-oophorectomy (BSO). *Eur J Surg Oncol.* 2006 Dec;32(10):1231-4 (IF 3.184)
- 44)45) Gotlieb WH, Bruchim I, Ben-Baruch G, Davidson B, Zeltser A, Andersen A, Olsen H. Doxorubicin levels in the serum and ascites of patients with ovarian cancer. *Eur J Surg Oncol.* 2006 Dec 14; (IF 3.184) [Epub ahead of print]
- 45)46) Grossman R, Hoffman C, Mardor Y, Biegon A. Quantitative MRI measurements of human fetal brain development in utero. *Neuroimage.* 2006 Nov 1; 33(2):463-70. (IF 5.288)
- 46)47) Haimi M, Elhasid R, Gershoni-Baruch R, Izraeli S, Wanders RJ, Mandel H. Myeloid dysplasia in familial 3-methylglutaconic aciduria. *J Pediatr Hematol Oncol.* 2006 Feb; 28(2):69-72. (IF 1.282)
- 47)48) Herr AL, Labopin M, Blaise D, Milpied N, Potter M, Michallet M, Heit W, Ferrara F, Esteve J, Arcese W, Ehninger G, Rowe JM, Kobbe G, Rosselet A, Bunjes D, Rio B, Brune M, Nagler A, Gorin NC, Frassoni F, Rocha V. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. *Leukemia.* 2007 Jan;21(1):129-35 (IF 6.612)
- 48)49) Hertzberg L, Betts DR, Raimondi SC, Schafer BW, Notterman DA, Domany E, Izraeli S. Prediction of chromosomal aneuploidy from gene expression data. *Genes Chromosomes Cancer.* 2007 Jan; 46(1):75-86. (IF 3.937)
- 49)50) Hochman E, Kinston S, Harmelin A, Gottgens B, Izraeli S. The SCL 3' enhancer responds to Hedgehog signaling during hemangioblast specification. *Exp Hematol.* 2006 Dec;34(12):1643-50. (IF 4.019)
- 50)51) Hochman E, Castiel A, Jacob-Hirsch J, Amariglio N, Izraeli S. Molecular Pathways Regulating Pro-migratory Effects of Hedgehog Signaling. *J Biol Chem.* 2006 Nov 10;281(45):33860-70. (IF 5.854)
- 51)52) Izraeli S. Perspective: chromosomal aneuploidy in leukemia--lessons from down syndrome. *Hematol Oncol.* 2006 Mar;24(1):3-6. (IF 1.774)
- 52)53) Izraeli S. Down's syndrome as a model of a pre-leukemic condition. *Haematologica.* 2006 Nov;91(11):1448-52 (IF 4.575) No abstract available
- 53)54) Katzenellenbogen M, Pappo O, Barash H, Klopstock N, Mizrahi L, Olam D, Jacob-Hirsch J, Amariglio N, Rechavi G, Mitchell LA, Kohen R, Domany E, Galun E,

- Goldenberg D. Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the mdr2-knockout mice. *Cancer Res.* 2006 Apr 15;66(8):4001-10. (IF 7.616)
- 54)55) Kalinkovich A, Tavor S, Avigdor A, Kahn J, Brill A, Petit I, Goichberg P, Tesio M, Netzer N, Naparstek E, Hardan I, Nagler A, Resnick I, Tsimanis A, Lapidot T. Functional CXCR4-Expressing Microparticles and SDF-1 Correlate with Circulating Acute Myelogenous Leukemia Cells. *Cancer Res.* 2006 Nov 15; 66(22):11013-11020. (IF 7.616)
- 55)56) Kaufman B, Laitman Y, Carvalho MA, Edelman L, Menachem TD, Zidan J, Monteiro AN, Friedman E. The P1812A and P25T brca1 and the 5164del4 BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews. *Genet Test.* 2006 Fall; 10(3):200-7. (IF 1.158)
- 56)57) Koren M, Kimmel G, Ben-Asher E, Gal I, Papa MZ, Beckmann JS, Lancet D, Shamir R, Friedman E. ATM haplotypes and breast cancer risk in Jewish high-risk women. *Br J Cancer.* 2006 May 22;94(10):1537-43 (IF 4.115)
- 57)58) Kroger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). *Bone Marrow Transplant.* 2006 Feb; 37(4):339-44. (IF 2.643)
- 58)59) Lapi E, Iovino A, Fontemaggi G, Soliera AR, Iacovelli S, Sacchi A, Rechavi G, Givol D, Blandino G, Strano S. S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation. *Oncogene.* 2006 Jun 22;25(26):3628-37 (IF 6.872)
- 59)60) Leiba M, Cahalon L, Shimoni A, Lider O, Zanin-Zhorov A, Hecht I, Sela U, Vlodavsky I, Nagler A. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells. *J Leukoc Biol.* 2006 Aug; 80(2):399-406. (IF 4.627)
- 60)61) Leibovitch I, Pinthus Y, Sella BA, Ramon J. Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients. *Harefuah.* 2006 Jan; 145(1):25-9, 78.
- 61)62) Leor J, Guetta E, Feinberg MS, Galski H, Bar I, Holbova R, Miller L, Zarin P, Castel D, Barbash IM, Nagler A. Human umbilical cord blood-derived CD133+ cells enhance

- function and repair of the infarcted myocardium. *Stem Cells*. 2006 Mar;24(3):772-80
(IF 6.094)
- 62)63) Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, Ken-Dror G, Almog S, Gak E. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. *Blood*. 2006 Nov 16; [Epub ahead of print]
(IF 10.131)
- 63)64) Lubina A, Cohen O, Barchana M, Liphshiz I, Vered I, Sadetzki S, Karasik A. Time trends of incidence rates of thyroid cancer in Israel: what might explain the sharp increase. *Thyroid*. 2006 Oct; 16(10):1033-40. (IF 2.175)
- 64)65) Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H, Papa MZ. Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. *J Endocrinol*. 2006 Dec;191(3):605-12
(IF 3.059)
- 65)66) Markel G, Seidman R, Stern N, Cohen-Sinai T, Izhaki O, Katz G, Besser M, Treves AJ, Blumberg RS, Loewenthal R, Mandelboim O, Orenstein A, Schachter J. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. *J Immunol*. 2006 Nov 1;177(9):6062-71 (IF 6.387)
- 66)67) Margalit O, Amram H, Amariglio N, Simon AJ, Shaklai S, Granot G, Minsky N, Shiloni A, Harmelin A, Givol D, Shohat M, Oren M, Rechavi G. BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma. *Blood*. 2006 Feb 15; 107(4):1599-607. (IF 10.131)
- 67)68) Menczer J, Chetrit A, Barda G, Lubin F, Fishman A, Dgani R, Modan B, Sadetzki S; National Israel Ovarian Cancer Group. Primary peritoneal carcinoma--Uterine involvement and hysterectomy. *Gynecol Oncol*. 2006 Mar; 100(3):565-9. (IF 2.251)
- 68)69) Menczer J, Chetrit A, Sadetzki S, Golan A, Levy T. Follow-up of ovarian and primary peritoneal carcinoma: The value of physical examination in patients with pretreatment elevated CA125 levels. *Gynecol Oncol*. 2006 Oct;103(1):137-40 (IF 2.251)
- 69)70) Menhel J, Levin D, Alezra D, Symon Z, Pfeffer R. Assessing the quality of conformal treatment planning: a new tool for quantitative comparison. *Phys Med Biol*. 2006 Oct 21;51(20):5363-75 (IF 2.683)
- 70)71) Mohty M, Nagler A, Killmann NM. Reduced-intensity conditioning allogeneic stem cell transplantation: hype, reality or time for a rethink? *Leukemia*. 2006 Oct; 20(10):1653-4. (IF 6.612) No abstract available

- 71)72) Moskovitz N, Kalinkovich A, Bar J, Lapidot T, Oren M. p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. *Cancer Res.* 2006 Nov 15; 66(22):10671-6. (IF 7.616)
- 72)73) Mor Y, Pinthus JH, Nadu A, Raviv G, Golomb J, Winkler H, Ramon J. Testicular fixation following torsion of the spermatic cord--does it guarantee prevention of recurrent torsion events? *J Urol.* 2006 Jan; 175(1):171-3; discussion 173-4 (IF 3.592)
- 73)74) Nagler R, Barness-Hadar L, Lieba M, Nagler A. Salivary antioxidant capacity in graft versus host disease. *Cancer Invest.* 2006 Apr-May; 24(3):269-77. (IF 1.849)
- 74)75) Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Horsman D, Rosen B, Isaacs C, Weber B, Foulkes W, Ainsworth P, Tung N, Eisen A, Friedman E, Eng C, Sun P, Narod SA. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. *Int J Cancer.* 2006 Jan 1;118(1):103-7 (IF 4.700)
- 75)76) Ostrovsky O, Korostishevsky M, Levite I, Leiba M, Galski H, Gazit E, Vlodavsky I, Nagler A. Characterization of HPSE Gene Single Nucleotide Polymorphisms in Jewish Populations of Israel. *Acta Haematol.* 2006 Nov 8;117(1):57-64 (IF 1.229)
- 76)77) Paglin S, Yahalom J. Pathways that regulate autophagy and their role in mediating tumor response to treatment. *Autophagy,* 2006 Oct-Dec;2(4):291-3
- 77)78) Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. *Oral Oncol.* 2006 Jun 4; (IF 2.266)
- 78)79) Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. *J Clin Oncol.* 2006 Jun 1; 24(16):2437-43. (IF 11.810)
- 79)80) Piestun D, Kochupurakkal BS, Jacob-Hirsch J, Zeligson S, Koudritsky M, Domany E, Amariglio N, Rechavi G, Givol D. Nanog transforms NIH3T3 cells and targets cell-type restricted genes. *Biochem Biophys Res Commun.* 2006 Apr 28;343(1):279-85 (IF 3.000)
- 80)81) Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: Ethical and safety

considerations for normal pediatric hematopoietic cell donors. *Pediatr Blood Cancer.* 2006 Jan 12; (IF 1.512)

81)82) Raanani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S, Nagler A, Polliack A, Ben-Bassat I, Even-Sapir E. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? *Ann Oncol.* 2006 Jan;17(1):117-22 (IF 4.319)

82)83) Raanani P, Shpilberg O, Ben-Bassat I. Extramedullary disease and targeted therapies for hematological malignancies--is the association real? *Ann Oncol.* 2006 Jun 21; [Epub ahead of print] (IF 4.319)

83)84) Ram Z, Cohen ZR, Harnof S, Tal S, Faibel M, Nass D, Maier SE, Hadani M, Mardor Y. Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain tumor therapy. *Neurosurgery.* 2006 Nov; 59(5):949-55; discussion 955-6. (IF 2.587)

84)85) Rashi-Elkeles S, Elkon R, Weizman N, Linhart C, Amariglio N, Sternberg G, Rechavi G, Barzilai A, Shamir R, Shiloh Y. Parallel induction of ATM-dependent pro- and antiapoptotic signals in response to ionizing radiation in murine lymphoid tissue. *Oncogene.* 2006 Mar 9; 25(10):1584-92. (IF 6.872)

85)86) Raviv G, Mor Y, Levron J, Shefi S, Zilberman D, Ramon J, Madgar I. Role of transrectal ultrasonography in the evaluation of azoospermic men with low-volume ejaculate. *J Ultrasound Med.* 2006 Jul; 25(7):825-9. (IF 1.091)

86)87) Rimon U, Duvdevani M, Garniek A, Golan G, Bensaid P, Ramon J, Morag B. Large renal angiomyolipomas: digital subtraction angiographic grading and presentation with bleeding. *Clin Radiol.* 2006 Jun;61(6):520-6 (IF 1.799)

87)88) Rosenburg N, Lalezari S, Landau M, Shenkman B, Seligsohn U, Israeli S. Trp207Gly in platelet glycoprotein Ibalpha is a novel mutation which disrupts the connection between the leucine-rich repeat domain and the disulfide loop structure and causes Bernard-Soulier syndrome. *J Thromb Haemost.* 2006 Nov 2; [Epub ahead of print] (IF 5.262)

88)89) Sade RB, Chetrit A, Figer A, Papa MZ, Flex D, Rizel S, Friedman E. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers. *Eur J Cancer.* 2006 Mar;42(5):650-54; (IF 3.706)

89)90) Sadetzki S, Chetrit A, Lubina A, Stovall M, Novikov I. Risk of thyroid cancer after childhood exposure to ionizing radiation for tinea capitis. *J Clin Endocrinol Metab.* 2006 Dec;91(12):4798-804

- 9091) Sadetzki S, Flint-Richter P. Transgenerational effects of parental exposure to ionizing radiation. *Harefuah*. 2006 Jul;145(7):516-21, 550, 549. Review. Hebrew
- 9192) Schwarz-Finsterle J, Stein S, Grobetamann C, Schmitt E, Trakhtenbrot L, Rechavi G, Amariglio N, Cremer C, Hausmann M. Comparison of triple helical COMBO-FISH and standard FISH by means of quantitative microscopic image analysis of abl/bcr positions in cell nuclei. *J Biochem Biophys Methods*. 2006 Sep 19; [Epub ahead of print]. (IF 1.201)
- 9293) Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M, Rechavi G, Hibshoosh H, Arber N. CD24 Is a New Oncogene, Early at the Multistep Process of Colorectal Cancer Carcinogenesis. *Gastroenterology*. 2006 Aug; 131(2):630-9. (IF 12.386)
- 9394) Schayek H, Krupsky M, Yaron P, Yellin A, Simansky DA, Friedman E. Genetic analyses of non-small cell lung cancer in Jewish Israeli patients. *IMAJ*. 2006 Mar; 8(3):159-63. (IF 0.547)
- 9495) Scope A, Sadetzki S, Sidi Y, Barzilai A, Trau H, Kaufman B, Catane R, Ehrenfeld M. Breast cancer and scleroderma. *Skinmed*. 2006 Jan-Feb;5(1):18-24
- 9596) Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. *Leukemia*. 2006 Feb; 20(2):322-8. (IF 6.612)
- 9697) Shulman O, Laitman Y, Vilan A, Leviav A, Friedman E. Monoclonal origin of anatomically distinct basal cell carcinomas. *J Invest Dermatol*. 2006 Mar; 126(3):676-9. (IF 4.406)
- 9798) Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A, Kedar-Barnes I, Shiri-Sverdlov R, Dagan E, Tsabari S, Shohat M, Catane R, King MC, Lahad A, Levy-Lahad E. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. *Proc Natl Acad Sci U S A*. 2006 Mar 7; 103(10):3770-4. (IF 10.231)
- 9899) Smeitink JA, Elpeleg O, Antonicka H, Diepstra H, Saada A, Smits P, Sasarman F, Vriend G, Jacob-Hirsch J, Shaag A, Rechavi G, Welling B, Horst J, Rodenburg RJ, van den Heuvel B, Shoubridge EA. Distinct Clinical Phenotypes Associated with a Mutation in the Mitochondrial Translation Elongation Factor EFTs. *Am J Hum Genet*. 2006 Nov; 79(5):869-77. (IF 12.649)

- 99)100) Stanchescu R, Betts DR, Yekutieli D, Ambros P, Cohen N, Rechavi G, Amariglio N, Trakhtenbrot L. SKY analysis of childhood neural tumors and cell lines demonstrates a susceptibility of aberrant chromosomes to further rearrangements. Cancer Lett. 2006 Nov 1; [Epub ahead of print] (IF 3.049)
- 100)101) Pfeffer MR. Radiation rescue for biochemical failure after surgery for prostate cancer: predictive parameters and an assessment of contemporary predictive models. Am J Clin Oncol. 2006 Oct;29(5):446-50.(IF 1.615)
- 101)102) Symon Z, Daignault S, Symon R, Dunn RL, Sanda MG, Sandler HM. Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy. Urology. 2006 Dec; 68(6):1224-9. (IF 2.139)
- 102)103) Symon Z, Menhel J, Alezra D, Pfeffer MR. Individual fraction optimization vs. first fraction optimization for multichannel applicator vaginal cuff high-dose-rate brachytherapy. Brachytherapy. 2006 Oct-Dec;5(4):211-5
- 103)104) Tal-Or P, Erlich S, Porat-Shliom N, Goldshmit Y, Ben-Baruch G, Shaharabani E, Kloog Y, Pinkas-Kramarski R. Ligand-independent regulation of ErbB4 receptor phosphorylation by activated ras. J Cell Biochem. 2006 Aug 15;98(6):1482-94 (IF 3.591)
- 104)105) van de Donk NW, Kroger N, Hegenbart U, Corradini P, Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood. 2006 Apr 15; 107(8):3415-6. (IF 10.131) No abstract available.
- 105)106) van de Donk NW, Kroger N, Hegenbart U, Corradini P, Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2006 Jun; 37(12):1135-41.(IF 2.643)
- 106)107) Vicus D, Korach J, Friedman E, Rizel S, Ben-Baruch G. Vulvar cancer metastatic to the breast. Gynecol Oncol. 2006 Sep 26. (IF 2.251)

- 107)108) Vlotides G, Cruz-Soto M, Rubinek T, Eigler T, Auernhammer CJ, Melmed S.
Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression
in pituitary folliculostellate TtT/GF cells. Mol Endocrinol. 2006 Dec;20(12):3321-35
- 108)109) Vrijheid M, Cardis E, Armstrong BK, Auvinen A, Berg G, Blaasaas KG,
Brown J, Carroll M, Chetrit A, Christensen HC, Deltour I, Feychting M, Giles GG,
Hepworth SJ, Hours M, Iavarone I, Johansen C, Klaeboe L, Kurttio P, Lagorio S, Lonn
S, McKinney PA, Montestrucq L, Parslow RC, Richardson L, Sadetzki S, Salminen T,
Schuz J, Tynes T, Woodward A; Interphone Study Group. Validation of short term
recall of mobile phone use for the Interphone study. Occup Environ Med. 2006
Apr;63(4):237-43
(IF 1.934)
- 109)110) Wald O, Weiss ID, Wald H, Shoham H, Bar-Shavit Y, Beider K, Galun E,
Weiss L, Flaishon L, Shachar I, Nagler A, Lu B, Gerard C, Gao JL, Mishani E, Farber J,
Peled A. IFN-gamma acts on T cells to induce NK cell mobilization and accumulation
in target organs. J Immunol. 2006 Apr 15; 176(8):4716-29. (IF 6.387)
- 110)111) Weitzen R, Tichler T, Kaufman B, Catane R, Shpatz Y. Body weight,
nutritional factors and physical activity--their influence on prognosis after breast cancer
diagnosis.
Harefuah. 2006 Nov; 145(11):820-5, 861. Hebrew.
- 111)112) Wiser A, Korach J, Gotlieb WH, Friedman E, Apter S, Ben-Baruch G.
Importance of accurate preoperative diagnosis in the management of aggressive
angiomyxoma: report of three cases and review of the literature. Abdom Imaging. 2006
May-Jun; 31(3):383-6. Review (IF 1.034)
- 112)113) Weizer-Stern O, Adamsky K, Amariglio N, Levin C, Koren A, Breuer W,
Rachmilewitz E, Breda L, Rivella S, Ioav Cabantchik Z, Rechavi G. Downregulation of
hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by
thalassaemic sera. Br J Haematol. 2006 Oct;135(1):129-38 (IF 4.080)
- 113)114) Weizer-Stern O, Adamsky K, Amariglio N, Rachmilewitz E, Breda L, Rivella
S, Rechavi G. mRNA expression of iron regulatory genes in beta-thalassemia
intermedia and beta-thalassemia major mouse models. Am J Hematol. 2006 Jun
5;81(7):479-483 (IF 1.612)
- 114)115) Williamson EA, Wolf I, O'Kelly J, Bose S, Tanosaki S, Koeffler HP. BRCA1
and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase
inhibitor p27(Kip). Oncogene. 2006 Mar 2;25(9):1391-9. (IF 6.872)

116) Wolf I, Kuchuck I, Kanety H. Adiponectin and Ghrelin: new players in cancer cachexia and carcinogenesis. Obesity and Metabolism. 2006 ;2:221-229

115)117) Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa MZ, Catane R, Kaufman B. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer. 2006 May;42(8):1077-82 (IF 3.706)

116)118) Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N, Oberman B, Catane R, Kaufman B, Shimon I. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer. 2006 Feb 15; 106(4):966-73. (IF 4.800)

117)119) Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY, Koeffler HP. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 2006 Aug 1;66(15):7818-23 (IF 7.616)

118)120) Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY, Koeffler HP. FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer. 2006 Dec 12; [Epub ahead of print] (IF 4.700)

119)121) Yarden RI, Papa MZ. BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions. Mol Cancer Ther. 2006; 5(6):1396-1404 (IF 5.171)

120)122) Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene. 2006 Jan 19; 25(3):359-69. (IF 6.872)